Overview

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital